<DOC>
	<DOCNO>NCT01660230</DOCNO>
	<brief_summary>The purpose study evaluate safety pharmacokinetic profile single multiple ascend intravenous dos 3K3A-APC healthy adult subject age 18-55 year .</brief_summary>
	<brief_title>Safety Pharmacokinetics Single Multiple Ascending Doses 3K3A-APC Healthy Adult Volunteers</brief_title>
	<detailed_description>This single-center , sequential-cohort , double-blind , placebo-controlled , single- multiple-ascending dose study . Eligible adult subject assign sequentially 1 10 cohort , successively high single dos , follow successively high multiple dos . Single IV Doses : 5 subject per cohort , age 18-55 , randomize 4:1 manner receive active drug ( 6 , 30 , 90 , 180 , 360 , TBD µg/kg ) receive match placebo ( Cohorts 1-6 ) . Multiple IV Doses : 8 subject per cohort , age 18-55 , randomize 3:1 manner receive active drug ( 90 , 180 , 360 , TBD µg/kg ) receive match placebo every 12 hour 5 dos ( Cohorts 7-10 ) . Single-Dose Cohorts Subjects receive single dose confine Phase 1 unit 12 hour prior dose , dose , 24 hour dose ( Study Day 1-2 ) observation PK sampling . Subjects return Study Day 4 ( ~72 hour infusion ) Study Day 15 additional safety evaluation . A 28-Day follow-up phone call make subject collect AEs occur within 28-days dose . Multiple-Dose Cohorts Subjects receive multiple dos confine Phase 1 unit 12 hour prior dose 24 hour follow last dose ( Study Day 1-4 ) observation PK sampling . Subjects return Study Day 6 ( ~72 hour last infusion ) Study Day 15 additional safety evaluation . A 28-Day follow-up phone call make subject collect AEs occur within 28-days last dose .</detailed_description>
	<criteria>1 . Healthy male nonpregnant , nonlactating female 2 . Both men woman childbearing potential ( i.e. , surgically sterile postmenopausal define age &gt; 40 year without menses ≥ 2 year ) must agree use barrier method contraception plus spermicide throughout study . 3 . Age 18 55 year , inclusive 4 . Body Mass Index ( BMI ) 19 30 kg/m2 , inclusive ( see APPENDIX B ) 5 . Willing able complete study visit 6 . Agreement abstain smoking drink alcoholic beverage 48 hour prior randomization last Study Day ( 15 ) 7 . Signed informed consent form ( ICF ) 1 . Any medical problem subject evaluate and/or treat 2 . Activated partial thromboplastin time ( aPTT ) great upper limit normal ( ULN ) 3 . Platelet count &lt; 125,000 cells/mm3 4. International Normalized Ratio ( INR ) &gt; 1.3 5 . Any clinically significant abnormality laboratory value ( chemistry , hematology , coagulation study , urinalysis see APPENDIX C ) 6 . Clinically significant abnormality electrocardiogram ( ECG ) 7 . Positive serum βHCG pregnancy test screening Study Day 1 ( woman , regardless childbearing potential ) 8 . Positive urine drug screen screen Study Day 1 ( see APPENDIX C ) 9 . Positive blood test hepatitis B surface antigen , hepatitis C antibody , HIV antibody 10 . Known family history bleed blood clot disorder 11 . History bleed diathesis 12 . History liver disease ongoing coagulopathy 13 . Use prescription nonprescription medication supplement within 7 day prior Study Day 1 , exclude hormonal contraceptive 14 . Use anticoagulant medication within 14 day prior Study Day 1 15 . Major surgery within 60 day prior Study Day 1 16 . Receipt investigational drug within 30 day prior Study Day 1 17 . Donation blood plasma within 30 day prior Study Day 1 18 . Any condition , opinion Site Investigator , may adversely affect safety subject , subject 's ability complete study , outcome study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>APC , 3K3A , 3K3A-APC , volunteer , healthy</keyword>
</DOC>